Piperacillin/Tazobactam versus Tobramycin-Based Antibiotic Prophylaxis for Type III Open Fractures

Area of Science:

• Orthopedic Surgery
• Infectious Diseases
• Pharmacology

Background:

• Type III open fractures carry a high risk of infection (up to 50%).
• Optimal antibiotic prophylaxis for these injuries remains debated due to limited comparative data.
• Adverse events (AEs) associated with different antibiotic regimens require investigation.

Purpose of the Study:

• To compare composite adverse events (AEs) in patients with Type III open fractures.
• To evaluate the safety and efficacy of piperacillin/tazobactam versus tobramycin-based prophylactic antibiotic regimens.
• To assess the rates of nephrotoxicity, surgical site infection (SSI), and re-admission with surgical intervention.

Main Methods:

• Retrospective single-center cohort study (January 2010 - December 2016).
• Inclusion criteria: patients with Type III open fractures receiving tobramycin or piperacillin/tazobactam prophylaxis.
• Primary outcome: composite AEs; Secondary outcomes: SSI at 30 and 60 days. Statistical analysis included Student t-, Mann-Whitney U, and Fisher exact tests.

Main Results:

• Eighty-five patients were analyzed; 29 events in the tobramycin group vs. 3 in the piperacillin/tazobactam group.
• Significantly lower rates of SSI at 30 days (4.3% vs. 27.5%, p=0.033) and 60 days (p=0.009) in the piperacillin/tazobactam group.
• No significant difference in composite AEs between the two antibiotic regimens.

Conclusions:

• Piperacillin/tazobactam prophylaxis is associated with a significantly lower incidence of surgical site infections in Type III open fractures compared to tobramycin.
• While composite adverse events did not differ, the reduction in SSI suggests a potential benefit of piperacillin/tazobactam.
• Further research may clarify the role of piperacillin/tazobactam in open fracture prophylaxis to optimize patient outcomes.